Literature DB >> 18833573

Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder.

Josephine A Mauskopf1, Gregory E Simon, Anupama Kalsekar, Christian Nimsch, Eduardo Dunayevich, Ann Cameron.   

Abstract

OBJECTIVE: To characterize the spectrum of clinical outcomes achieved with depression treatment and the associated impact on quality of life (QOL), functional status, overall well-being, health-care costs, and productivity. SOURCES: Electronic databases including Medline were searched for English language sources between 1995 and 2007 using key words of depression, nonresponse, partial response, and remission and QOL, functional status, utility, cost, and productivity. STUDY SELECTION: Relevant abstracts were obtained for 488 references and full-text articles were reviewed that included primary data and compared outcomes by treatment response. Data were abstracted from 26 full-text articles. DATA ABSTRACTION: Detailed evidence tables were prepared with the relevant data as well as information on the study design. All data abstracted were checked for accuracy. synthesis: Treatment remitters and partial responders reported clinically and statistically significant improvements in QOL, functional status, and overall well-being compared to nonresponders. Annual health-care costs and productivity losses were significantly lower for remitters and partial responders compared to nonresponders.
CONCLUSIONS: The reduced disease burden for remitters and partial responders compared to nonresponders indicates that new treatment strategies that improve the rates of response/remission with initial treatment might have value to patients and to society. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 18833573     DOI: 10.1002/da.20505

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  30 in total

1.  A model to transfer trial-based pharmacoeconomic analyses to clinical practice.

Authors:  Afschin Gandjour
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

2.  STAR*D and Measurement-Based Care for Depression: Don't Toss Out the Baby!

Authors:  Raymond W Lam; Sidney H Kennedy
Journal:  Can J Psychiatry       Date:  2015-01       Impact factor: 4.356

3.  Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005-2008.

Authors:  Ruth S Shim; Peter Baltrus; Jiali Ye; George Rust
Journal:  J Am Board Fam Med       Date:  2011 Jan-Feb       Impact factor: 2.657

4.  Low dietary or supplemental zinc is associated with depression symptoms among women, but not men, in a population-based epidemiological survey.

Authors:  Nancy N Maserejian; Susan A Hall; John B McKinlay
Journal:  J Affect Disord       Date:  2011-10-24       Impact factor: 4.839

5.  Calotropis procera attenuates chronic unpredictable mild stress-induced depression in experimental animals.

Authors:  Debapriya Garabadu; Neha Srivastava; Yogesh Murti
Journal:  Metab Brain Dis       Date:  2019-07-26       Impact factor: 3.584

6.  Improvement in functional outcomes with adjunctive aripiprazole versus placebo in major depressive disorder: a pooled post hoc analysis of 3 short-term studies.

Authors:  Tanya J Fabian; Zachary J Cain; Diane Ammerman; James M Eudicone; Yan Tang; Linda M Rollin; Robert A Forbes; Robert M Berman; Ross A Baker
Journal:  Prim Care Companion CNS Disord       Date:  2012-12-20

Review 7.  The role of dopaminergic agents in improving quality of life in major depressive disorder.

Authors:  Waguih William IsHak; Michael Davis; Jessica Jeffrey; Konstantin Balayan; Robert N Pechnick; Kara Bagot; Mark Hyman Rapaport
Journal:  Curr Psychiatry Rep       Date:  2009-12       Impact factor: 5.285

8.  Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.

Authors:  Sonja Horstmann; Susanne Lucae; Andreas Menke; Johannes M Hennings; Marcus Ising; Darina Roeske; Bertram Müller-Myhsok; Florian Holsboer; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2009-11-18       Impact factor: 7.853

9.  Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats.

Authors:  Gregory V Carr; Debra A Bangasser; Thelma Bethea; Matthew Young; Rita J Valentino; Irwin Lucki
Journal:  Neuropsychopharmacology       Date:  2009-11-18       Impact factor: 7.853

10.  Contemporary concepts in the pharmacotherapy of depression in older people.

Authors:  Carlos Rojas-Fernandez; Mina Mikhail
Journal:  Can Pharm J (Ott)       Date:  2012-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.